Lota Zoth

Lota S.
Zoth is currently an Independent Director at First Financial Bankshares, Inc. since 2026, at enGene Therapeutics, Inc. since 2023, and at Inovio Pharmaceuticals, Inc. since 2018.
Former roles include Chairman at Zymeworks BC, Inc. from 2019 to 2022; Chairman at Orexigen Therapeutics, Inc. from 2018 to 2019; Independent Director at NewLink Genetics Corp.; Director at Aeras Global TB Vaccine Foundation from 2011 to 2018; Non-Executive Director at Hyperion Therapeutics, Inc. in 2015; Director at Ikaria, Inc. from 2007 to 2014; Independent Director at Spark Therapeutics, Inc. from 2016 to 2019; Senior Independent Non-Executive Director at Niox Group Plc from 2018 to 2019; Lead Independent Director at Zymeworks, Inc. from 2022 to 2023; Independent Director at 89bio, Inc. from 2020 to 2025; Independent Director at Lumos Pharma, Inc. from 2012 to 2024; Chief Accounting Officer & Controller at PepsiCo, Inc.; Senior Vice President & Controller at PSINet, Inc. in 2002; Vice President-Finance at Marriott International, Inc.; Auditor at Ernst & Young LLP (Missouri); Chief Accounting Officer, VP & Controller at Sodexho Marriott Services, Inc.; Chief Financial Officer & Senior Vice President at MedImmune LLC from 2004 to 2007.
Education includes undergraduate studies at Texas Tech University.